Adaptimmune Therapeutics plc (ADAP)
Largest Insider Buys in Sector
ADAP Stock Price History Chart
ADAP Stock Performance
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Activity of Adaptimmune Therapeutics plc
Over the last 12 months, insiders at Adaptimmune Therapeutics plc have bought $0 and sold $197,472 worth of Adaptimmune Therapeutics plc stock.
On average, over the past 5 years, insiders at Adaptimmune Therapeutics plc have bought $10.09M and sold $1.88M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 39,000 shares for transaction amount of $11,326 was made by Wood Gavin (Chief Financial Officer) on 2022‑05‑20.
List of Insider Buy and Sell Transactions, Adaptimmune Therapeutics plc
| 2024-06-18 | Sale | Piccina Cintia | Chief Commercial Officer | 24,531 0.0086% | $0.93 | $22,814 | -0.38% | |
| 2024-01-17 | Sale | Rawcliffe Adrian | Chief Executive Officer | 30,080 0.0124% | $0.67 | $20,244 | +61.54% | |
| 2024-01-17 | Sale | Norry Elliot | Chief Medical Officer | 18,276 0.0075% | $0.67 | $12,300 | +61.54% | |
| 2024-01-17 | Sale | Lunger John | Chief Patient Supply Officer | 18,114 0.0075% | $0.67 | $12,191 | +61.54% | |
| 2024-01-17 | Sale | Bertrand William C JR | Chief Operating Officer | 18,908 0.0078% | $0.67 | $12,725 | +61.54% | |
| 2024-01-16 | Sale | Rawcliffe Adrian | Chief Executive Officer | 9,304 0.0046% | $0.79 | $7,350 | +61.95% | |
| 2024-01-16 | Sale | Lunger John | Chief Patient Supply Officer | 4,681 0.0023% | $0.79 | $3,698 | +61.95% | |
| 2024-01-16 | Sale | Bertrand William C JR | Chief Operating Officer | 4,681 0.0023% | $0.79 | $3,698 | +61.95% | |
| 2024-01-16 | Sale | Norry Elliot | Chief Medical Officer | 2,287 0.0011% | $0.79 | $1,807 | +61.95% | |
| 2024-01-12 | Sale | Rawcliffe Adrian | Chief Executive Officer | 17,257 0.0078% | $0.85 | $14,739 | +39.46% | |
| 2024-01-12 | Sale | Norry Elliot | Chief Medical Officer | 7,799 0.0035% | $0.85 | $6,661 | +39.46% | |
| 2024-01-12 | Sale | Lunger John | Chief Patient Supply Officer | 5,220 0.0024% | $0.85 | $4,458 | +39.46% | |
| 2024-01-12 | Sale | Bertrand William C JR | Chief Operating Officer | 5,220 0.0024% | $0.85 | $4,458 | +39.46% | |
| 2024-01-11 | Sale | Rawcliffe Adrian | Chief Executive Officer | 11,945 0.005% | $0.84 | $9,994 | +33.35% | |
| 2024-01-11 | Sale | Norry Elliot | Chief Medical Officer | 4,009 0.0017% | $0.84 | $3,354 | +33.35% | |
| 2024-01-11 | Sale | Lunger John | Chief Patient Supply Officer | 4,009 0.0017% | $0.84 | $3,354 | +33.35% | |
| 2024-01-11 | Sale | Bertrand William C JR | Chief Operating Officer | 4,009 0.0017% | $0.84 | $3,354 | +33.35% | |
| 2023-09-01 | Sale | Rawcliffe Adrian | Chief Executive Officer | 2,403 0.001% | $0.78 | $1,874 | +11.39% | |
| 2023-08-01 | Sale | Lunger John | Chief Patient Supply Officer | 3,096 0.0013% | $0.91 | $2,804 | -7.89% | |
| 2023-07-10 | Sale | Menzel Garry E | director | 47,702 0.0283% | $0.91 | $43,447 | -5.17% |
Insider Historical Profitability
| Menzel Garry E | director | 75056 0.0331% | $0.83 | 0 | 1 | |
| Rawcliffe Adrian | Chief Executive Officer | 44848 0.0198% | $0.83 | 0 | 27 | |
| Piccina Cintia | Chief Commercial Officer | 38293 0.0086% | $0.83 | 0 | 3 | |
| Lunger John | Chief Patient Supply Officer | 7785 0.0034% | $0.83 | 0 | 23 | |
| Norry Elliot | Chief Medical Officer | 7785 0.0034% | $0.83 | 0 | 16 | |
| Bertrand William C JR | Chief Operating Officer | 7785 0.0034% | $0.83 | 1 | 18 | +23.78% |
| BARRIS PETER J | 10 percent owner | 82978668 36.5654% | $0.83 | 7 | 0 | <0.0001% |
| BARRETT M JAMES | 10 percent owner | 82978668 36.5654% | $0.83 | 7 | 0 | <0.0001% |
| KERINS PATRICK J | 10 percent owner | 82978668 36.5654% | $0.83 | 7 | 0 | <0.0001% |
| Viswanathan Ravi | 10 percent owner | 82978668 36.5654% | $0.83 | 7 | 0 | <0.0001% |
| New Enterprise Associates 14, L.P. | 10 percent owner | 82978668 36.5654% | $0.83 | 7 | 0 | <0.0001% |
| MOTT DAVID M | 19500000 8.5929% | $0.83 | 8 | 0 | <0.0001% | |
| Behbahani Ali | director | 19500000 8.5929% | $0.83 | 2 | 0 | <0.0001% |
| BASKETT FOREST | 10 percent owner | 19500000 8.5929% | $0.83 | 8 | 0 | <0.0001% |
| SANDELL SCOTT D | 10 percent owner | 19500000 8.5929% | $0.83 | 8 | 0 | <0.0001% |
| Sonsini Peter W. | 10 percent owner | 19500000 8.5929% | $0.83 | 8 | 0 | <0.0001% |
| Florence Anthony A. Jr. | 10 percent owner | 19500000 8.5929% | $0.83 | 8 | 0 | <0.0001% |
| Thompson Peter A. | director | 4901310 2.1598% | $0.83 | 4 | 7 | <0.0001% |
| ORBIMED ADVISORS LLC | director | 4901310 2.1598% | $0.83 | 4 | 7 | <0.0001% |
| Sigal Charles Elliott | director | 314100 0.1384% | $0.83 | 4 | 0 | <0.0001% |
| Wood Gavin | Chief Financial Officer | 96000 0.0423% | $0.83 | 3 | 0 | <0.0001% |
| Amado Rafael | President, R&D | 17237 0.0076% | $0.83 | 0 | 2 | |
| Alleva Lawrence M | director | 12600 0.0056% | $0.83 | 3 | 0 | <0.0001% |
| Binder-Scholl Gwendolyn Knowlton | Chief Technology Officer | 2487 0.0011% | $0.83 | 0 | 3 | |
| Noble James | director | 0 0% | $0.83 | 0 | 2 | |
| TAYTON-MARTIN HELEN KATRINA | Chief Business Officer | 0 0% | $0.83 | 0 | 2 |
Institutional Investor Ownership
| Matrix Capital Management Company, L.P. | $61.58M | 15.25 | 38.97M | 0% | +$0 | 0.57 | |
| Ecor1 Capital Llc | $43.3M | 10.72 | 27.4M | New | +$43.3M | 1.1 | |
| Nea Management Company Llc | $26.99M | 6.68 | 17.08M | 0% | +$0 | 0.31 | |
| Baillie Gifford Co | $25.08M | 6.21 | 15.87M | -0.25% | -$63,618.70 | 0.02 | |
| Baker Bros Advisors LP | $17.04M | 4.22 | 10.79M | -1.66% | -$287,970.80 | 0.21 | |
| Long Focus Capital Management Llc | $16.88M | 4.18 | 10.68M | -11.61% | -$2.22M | 1.96 | |
| PFM Health Sciences | $16.47M | 4.08 | 10.42M | 0% | +$0 | 0.46 | |
| MPM Asset Management LLC | $8.78M | 2.17 | 5.56M | 0% | +$0 | 3.58 | |
| Bioimpact Capital Llc | $8.05M | 1.99 | 5.1M | 0% | +$0 | 1.3 | |
| Bank of America | $7.38M | 1.83 | 4.67M | -0.64% | -$47,663.86 | <0.01 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $3.83M | 0.95 | 2.43M | 0% | +$0 | 0.1 | |
| Fidelity Investments | $2.74M | 0.68 | 1.73M | -0.03% | -$910.08 | <0.0001 | |
| Tang Capital Management, LLC | $2.28M | 0.57 | 1.44M | -67.09% | -$4.65M | 0.01 | |
| Renaissance Technologies | $2.2M | 0.55 | 1.39M | +1.57% | +$34,026.81 | <0.01 | |
| JPMorgan Chase | $1.45M | 0.36 | 915,030 | -1.42% | -$20,846.53 | <0.0001 | |
| Millennium Management LLC | $1.3M | 0.32 | 825,179 | +87.1% | +$606,952.34 | <0.01 | |
| Redmile Group | $1.13M | 0.28 | 715,607 | 0% | +$0 | 0.04 | |
| Cubist Systematic Strategies | $1.07M | 0.26 | 675,882 | +1,853.02% | +$1.01M | 0.01 | |
| Acuitas Investments, LLC | $850,547.00 | 0.21 | 538,321 | +12.2% | +$92,480.54 | 0.45 | |
| Rathbone Brothers | $683,852.00 | 0.17 | 432,818 | 0% | +$0 | <0.01 | |
| Morgan Stanley | $589,783.00 | 0.15 | 373,281 | -80.92% | -$2.5M | <0.0001 | |
| Gsa Capital Partners Llp | $585,000.00 | 0.15 | 370,179 | -27.25% | -$219,077.70 | 0.05 | |
| DAFNA Capital Management, LLC | $538,881.00 | 0.13 | 341,064 | -2.85% | -$15,800.00 | 0.13 | |
| State Street | $493,810.00 | 0.12 | 312,538 | +2.36% | +$11,379.16 | <0.0001 | |
| BlackRock | $457,707.00 | 0.11 | 289,688 | +61.31% | +$173,969.05 | <0.0001 | |
| Key Client Fiduciary Advisors Llc | $424,475.00 | 0.11 | 268,655 | New | +$424,475.00 | 0.06 | |
| Marshall Wace | $401,340.00 | 0.1 | 254,013 | New | +$401,340.00 | <0.01 | |
| Citadel Advisors LLC | $385,032.00 | 0.1 | 243,691 | -92.83% | -$4.99M | <0.0001 | |
| UBS | $310,780.00 | 0.08 | 196,696 | +696.57% | +$271,765.02 | <0.0001 | |
| Harbor Capital Advisors Inc | $297,000.00 | 0.07 | 188,070 | +27.3% | +$63,701.74 | 0.04 | |
| Geode Capital Management | $186,296.00 | 0.05 | 117,909 | 0% | +$0 | <0.0001 | |
| CAPTRUST | $176,884.00 | 0.04 | 111,952 | +548.85% | +$149,622.70 | <0.0001 | |
| LINSCO PRIVATE LEDGER CORP | $171,992.00 | 0.04 | 108,856 | New | +$171,992.00 | <0.0001 | |
| Goldman Sachs | $169,948.00 | 0.04 | 107,562 | +573.15% | +$144,701.17 | <0.0001 | |
| Tealwood Asset Management | $155,771.00 | 0.04 | 98,589 | 0% | +$0 | 0.04 | |
| Boulder Hill Capital Management Lp | $143,464.00 | 0.04 | 90,800 | New | +$143,464.00 | 0.06 | |
| Cibc Private Wealth Group Llc | $112,780.00 | 0.03 | 76,721 | New | +$112,780.00 | <0.0001 | |
| Jump Financial Llc | $106,911.00 | 0.03 | 67,665 | New | +$106,911.00 | <0.01 | |
| Northern Trust | $90,850.00 | 0.02 | 57,500 | +0.13% | +$121.66 | <0.0001 | |
| Susquehanna International Group | $89,014.00 | 0.02 | 56,338 | -0.89% | -$802.64 | <0.0001 | |
| Wells Fargo | $85,592.00 | 0.02 | 54,172 | -3.57% | -$3,167.91 | <0.0001 | |
| Barclays | $79,000.00 | 0.02 | 50,061 | 0% | +$0 | <0.0001 | |
| Two Sigma Advisers LP | $72,896.00 | 0.02 | 46,137 | -22.9% | -$21,645.86 | <0.0001 | |
| Oppenheimer Holdings | $69,255.00 | 0.02 | 43,832 | -12.52% | -$9,908.24 | <0.01 | |
| Wealth Enhancement Advisory Services LLC | $50,938.00 | 0.01 | 32,239 | 0% | +$0 | <0.0001 | |
| Css Llc Il | $48,509.00 | 0.01 | 30,702 | 0% | +$0 | 0.01 | |
| Janney Montgomery Scott LLC | $47,000.00 | 0.01 | 30,000 | 0% | +$0 | <0.0001 | |
| Main Street Financial Solutions Llc | $49,280.00 | 0.01 | 31,190 | 0% | +$0 | 0.01 | |
| Simon Quick Advisors, LLC | $47,400.00 | 0.01 | 30,000 | 0% | +$0 | <0.01 | |
| Jtc Employer Solutions Trustee Ltd | $41,000.00 | 0.01 | 26,156 | New | +$41,000.00 | <0.01 |